GV20 Therapeutics (GV20)has entered into a strategic research collaboration with Mitsubishi Tanabe Pharma Corporation (MTPC). Under this collaboration, MTPC will leverage GV20's antibodies, which are specifically directed against novel tumor antigen targets discovered through GV20's proprietary STEAD AI platform, to generate potentially first-in-class antibody-drug conjugates.
"This agreement underlines the strength of GV20's STEAD platform in discovering novel tumor targets and human-derived antibodies." said Ying Gong, Ph.D., Chief Business Officer of GV20. "We are excited to partner with MTPC, leveraging their deep expertise in linker-payload technology and therapeutics development, to advance innovative antibody-drug conjugate (ADC) therapies against these novel targets."
Under the terms of the agreement, GV20 will receive an upfront payment and is eligible for milestone payments. MTPC will receive an exclusive right to negotiate a license to these antibodies during the collaboration term.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox!
Sign up now!